drugset / Trial / NCT05037097
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults previously vaccinated and not previously vaccinated against SARS-CoV-2.
Timeline
- Start
- 2021-08-30
- Primary completion
- 2023-12-19
- Completion
- 2023-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARCT-021 | Messenger RNA (mRNA) | — | — |
| Subject | ARCT-154 | Small activating RNA (saRNA) | — | — |
| Subject | ARCT-165 | Unknown | — | — |